

Subject Index

Italic page numbers indicate figures; page number followed by “t” indicate tables.

A

- Acoustic neuroma, 35–36, 47–58
bilateral, 47
cystic, 47, 58
genetic factors and, 47
growth patterns of, 47
hearing loss due to, 47, 49, 50
management algorithm for, 50
management options for, 47
in neurofibromatosis 3, 47, 55, 57
observation with serial imaging of, 47
radiosurgery for, 49–58
 clinical results of gamma knife radiosurgery, 52–54, 52–55
 clinical results of LINAC radiosurgery, 55
 clinical results of proton beam radiosurgery, 55
 clinical results of stereotactic radiation therapy, 55–56
 compared with microsurgery, 56–57
 dose delivery for, 52
 dose planning for, 51, 51
 dose prescription for, 51–52
 facial nerve and trigeminal nerve function after, 55
 after failed microsurgery, 57
 follow-up evaluations after, 52
 gamma knife radiosurgery, 35–36, 49
 goals of, 49
 hearing preservation after, 53–54, 53–54
 microsurgery after, 57–58
 myths about, 57–58
 in neurofibromatosis, 3, 55, 57
 outcomes of, 48t, 49t
 patient evaluation for, 49–50
 postoperative care after, 52
 radiation-induced cancers and, 58
 technique for, 50–51
 tumor growth control after, 52–53, 52–53
surgical removal of, 47–49
 compared with radiosurgery, 56–57
 complications of, 48
 eye-related problems after, 49
 facial function after, 35, 36, 47–48
 hearing outcome after, 3, 35, 48
 patients' perspective on outcome of, 48–49
 after radiosurgery, 57–58
 recurrence/residual tumor after, 48
 surgical approaches for, 47
 tinnitus after, 48
- Adrenocorticotropic hormone excess. *See* Cushing's disease
- Allograft, to enhance spinal fusion, 63–64
- Alternative Dispute Resolution, 122
- American Association of Neurological Surgeons (AANS), 10, 145
- 5-Aminolevulinic acid (ALA), in resection of gliomas, 20–26, 21
 dexamethasone pretreatment for, 21
 dosage of, 21
 equipment for, 22–23, 23
 extent of resection, 24
 implementation during surgery, 23, 23
 intraoperative photosensitization of brain tissue by, 22
 light protection for, 21–22
 pharmacokinetics of, 21
 photobleaching and, 23–24
 pitfalls in, 24, 24–25, 25
 safety and efficacy of, 20, 21
 timing of administration of, 21
- Amundsen, Roald, 10, 11, 12
- Anterior approach for cervical ossification of posterior longitudinal ligament (OPLL), 127–129, 128–129, 130
- Apparent diffusion coefficient (ADC) maps, for tumor resection, 15, 15
- Arteriovenous malformations (AVMs)
 management options for, 108, 109
 radiosurgery for, 108–117
 dosage for, 110, 110
 dural AVMs, 116
 early adverse effects of, 112
 embolization before, 108, 110, 116–117
 future directions for, 117
 imaging changes after, 112–113, 113
 initial experience with, 108–109
 late complications of, 114
 management of large AVMs, 115
 management of residual AVM after, 114–115, 115
 permanent sequelae of, 113, 114t
 Pittsburgh experience with, 109–111, 109t
 probability of AVM obliteration with, 112
 risk of hemorrhage after, 111–112, 112t
 staged volume radiosurgery, 110–111, 115–116
 technical considerations for, 109–111, 110t
 risk of hemorrhage from, 108, 111
- Astrocytoma
 anaplastic, 20
 Daumas-Duport classification of, 39, 39
 fibrillary, 38, 39
 gamma knife radiosurgery for, 37t, 38–39
 grade II, 39, 39
 juvenile pilocytic, 38, 38

B

- Backlund, Erik-Olof, 76, 85
- Ballard, Robert, 3, 3
- BCNU-impregnated polymer implantation, 27–29, 28, 29
- Bioactive strategies to enhance spinal fusion, 65–66, 65t
 bone marrow aspirate and blood spin-down technologies, 64, 66
 bone morphogenetic proteins, 65–66
 composite technologies, 66
 cytokines and other inductive agents, 66
 gene therapy, 66
- Biosensing strategies to enhance spinal fusion, 68–69, 70
 complexity of bone loading, 68–69, 71

optimizing bone loading and bone-loading rates, 69

Bladder function in spinal cord injury, improved by CB₂ agonist therapy (mouse), 173, 174, 175, 176

Blood spin-down technologies, to enhance spinal fusion, 64, 66

Bone graft substitutes, to enhance spinal fusion, 63–65

- allograft, 63–64
- components of bone healing, 64
- demineralized bone matrix, 65
- xenograft, 65

Bone healing

- components of, 64
- phases of, 63, 64

Bone marrow aspirate (BMA), to enhance spinal fusion, 64, 66

Bone morphogenetic proteins (BMPs), to enhance spinal fusion, 65–66

Brain abscess, image-guided management of, 81

Brain cysts

- delayed formation after radiosurgery for AVMs, 114
- stereotactic aspiration of, 80, 80t, 80t

Brain hemorrhage

- after radiosurgery for cavernous malformations, 97–99
- risk from AVMs, 108, 111
- after radiosurgery, 111–112, 112t
- after stereotactic procedures, 79–80, 80t

Brain metastases, radiosurgery for, 37t, 40–42, 41

- metastases from melanoma and renal cell carcinoma, 150–158
- clinical management strategy for, 150–151
- data collection for analysis of, 150
- local control rate for, 154–156, 154t, 155–156, 157
- patient population for, 151, 152t
- planning and implementation of, 151
- response and survival after, 151–154, 152–153, 153t, 157
- statistical analysis of, 151
- whole-brain radiotherapy and, 156, 156, 157–158

Perfexion gamma knife, 44

Brain tumor resection, 12–18

- detection of neural network activity for, 18, 18
- emerging neuroimaging technologies for, 15–17
- apparent diffusion coefficient maps, 15, 15
- diffusion tensor imaging, 17, 17, 20, 160–163, 161–162
- functional magnetic resonance imaging, 16
- magnetic resonance perfusion and cerebral blood volume, 16, 16–17
- magnetoencephalography, 17
- quantitative T2 imaging, 15–16, 16
- fluorescence-guided resection of gliomas using ALA, 20–26, 21
- intraoperative stimulation mapping for, 17, 18
- physiological imaging: magnetic resonance spectroscopy for, 12–15, 15

Brain tumors. *See also specific tumors*

- drug delivery techniques for, 27–33
- convection-enhanced delivery, 29–33, 30, 31
- drug-impregnated polymer implantation, 27–29, 28, 29
- herpes simplex virus-mediated boost radiosurgery for, 40, 40
- innovation in glioma management, 37–40
- grade II astrocytoma/oligodendroglioma, 39, 39, 39t
- juvenile pilocytic astrocytoma, 38, 38

- malignant gliomas, 39–40
- innovation in skull base tumor management, 35–37, 36, 36t–38t
- metastatic (*See Brain metastases*)
- role of neurosurgeon in management of, 35–44

Brainstem cavernous malformations, 88–94

- case examples of, 91–93, 91–93
- epidemiology of, 88
- evaluation of, 89
- genes associated with, 88, 89t
- intrinsic vs. exophytic, 94
- management of, 90, 90t
- operative technique for, 93
- pathogenesis of, 88–89
- in pregnancy, 91, 93
- presentation of, 89
- prognosis for, 10
- radiosurgery for, 90, 90t
- surgical approaches to, 93–94, 94t

BrainSuite, 160, 161

Brown, Russ, 76

C

Cannabinoid receptors, 172–176

- CB₂ receptor activation in murine spinal cord injury, 172–176
- bladder function improved by, 173, 174, 175, 176
- CB₂ agonist (O-1966) properties and injection, 173
- locomotive function improved by, 173–174, 174
- TNF- α expression decreased by, 172, 174–175, 175
- upregulation of, 173, 174
- effects of CB₁ receptor activation, 175–176
- psychoactive effects of, 172, 176
- sites of expression of, 172, 175–176

Carmustine-impregnated polymer implantation, 27–29, 28, 29

Cavernous malformations

- of brainstem, 88–94
- case examples of, 91–93, 91–93
- epidemiology of, 88
- evaluation of, 89
- genes associated with, 88, 89t
- intrinsic vs. exophytic, 94
- management of, 90, 90t
- operative technique for, 93
- pathogenesis of, 88–89
- in pregnancy, 91, 93
- presentation of, 89
- prognosis for, 10
- radiosurgery for, 90, 90t
- surgical approaches to, 93–94, 94t
- radiosurgery for, 90, 90t, 97–99, 98
- hemorrhage protection and, 98–99
- rationale for, 97–98
- results of, 98
- seizure protection and, 99, 104, 106
- seizures secondary to, 101–107
- arguments for early surgery in, 102
- case examples of, 104–105, 104–105
- lesionectomy for, 102, 103t, 104, 105–106

lesionectomy plus electrocorticography-guided resection for, 102–103
 mechanisms of, 106–107
 medical intractability of, 101–102
 in patients with multiple cavernous malformations, 106
 postsurgical anti-epileptic drug treatment for, 106
 questions about management of, 101, 106
 radiosurgery for, 99, 104, 106
 safety of surgery for, 106
 subdural electrode monitoring to define epileptogenic zone in, 103–104, 106
 treatment options for, 102–104
 treatment recommendations for, 105, 105

Cerebrospinal fluid leak, after acoustic neuroma removal, 48

Chemotherapy
 for juvenile pilocytic astrocytoma, 38
 for malignant gliomas, 20, 27–33
MSH6 inactivation and emergent temozolomide resistance in glioblastomas, 165–169, 166–169
 surgically mediated delivery of, 27–33, 28–31
 convection-enhanced delivery, 29–33, 30, 31
 drug-impregnated polymer implantation, 27–29, 28, 29

Collateral-source payments, 122

Computed tomography (CT)
 of cervical ossification of posterior longitudinal ligament, 126
 intraoperative, 76–77, 77
 for brain abscess, 81
 for craniotomy, 80
 development of dedicated stereotactic operating room, 76, 84, 84
 for endoscopic-assisted surgery, 82, 82
 for frame-based stereotactic surgery, 77–79, 77–79
 for frameless stereotactic surgery, 83
 for functional neurosurgery, 81–82

Congress of Neurological Surgeons, 10

Contingency fee, 122

Convection-enhanced drug delivery (CED), 29–33
 clinical trials of chemotherapeutic compounds, 30
 clinical trials of recombinant cytotoxic proteins, 30–32
 future applications of, 32–33
 pharmacokinetics and properties of, 29–30, 30
 of radiolabeled chimeric monoclonal antibodies, 32
 surrogate imaging tracers in tracking of, 30
 technique for, 29

Cook, Frederick, 11, 11

Cortical brain stimulation, 2, 3

Council of Medical Specialty Societies, 145

Council of State Neurosurgical Societies, 145

Craniopharyngioma, stereotactic aspiration of, 80, 80

Craniotomy, image-guided, 76, 80–81

Cushing, Harvey, 4, 5

Cushing's disease, 141–143
 fractionated radiation therapy for, 141
 initial transsphenoidal surgery for, 141, 143
 results of, 142, 142
 management options for recurrent or refractory disease, 141
 radiosurgery for, 141, 142–143, 143

 repeat transsphenoidal surgery for, 141, 142, 143

Cytokines
 to enhance spinal fusion, 66
 TNF- α expression decreased by CB₂ agonist in spinal cord injury, 172, 174–175, 175

Cytotoxic proteins, convection-enhanced delivery of, 30–31

D

Dandy, Walter, 88

Daumas-Duport classification of astrocytomas, 39, 39

Degenerative spondylolisthesis, SPORT study of, 72, 75

Demineralized bone matrix (DBM), to enhance spinal fusion, 65

Dexamethasone, pretreatment for ALA administration, 21

Diffusion tensor imaging (DTI), for tumor resection, 17, 17, 20, 160–163, 161–162

Direct current stimulation, to enhance spinal fusion, 67

Drug delivery techniques, 27–33
 convection-enhanced delivery, 29–33, 30, 31
 drug-impregnated polymer implantation, 27–29, 28, 29

Drug-impregnated polymer implantation, 27–29, 28, 29
 future applications of, 28–29
 pharmacokinetics and properties of, 27–28, 29
 studies for recurrent malignant gliomas, 28
 studies with newly diagnosed malignant gliomas, 28
 technique for, 27, 28

E

Electrophysiological strategies to enhance spinal fusion, 66–67, 67

Embolization before radiosurgery for AVMs, 108, 110, 116–117

Endoscopic-assisted surgery, image-guided, 82, 82, 83

Ethical issues in psychosurgery, 138–139

Expert witness requirements, 122

Exploration, neurosurgery as, 2–8, 2–12, 10–12

F

Facial nerve function, after acoustic neuroma surgery, 35, 36, 47–48, 55

Franklin, John, 6–8, 8, 11

Freeman, Walter, 138–139

Functional neurosurgery, 76, 81–82, 81t

G

Gamma knife radiosurgery. *See* Radiosurgery

Ganglioglioma, gamma knife radiosurgery for, 39

Gene therapy, to enhance spinal fusion, 66

Geographical neurosurgical workforce analysis
 AANS data sets for, 145–146
 data analysis, 146
 in future, 148
 general trends, 146, 146
 methodology of, 145
 professional liability insurance environment and, 145, 146, 147–148
 rank order analysis, 146–147, 147, 147t

U.S. census data sets for, 146
 Gliadel wafer, 27–29, 28, 29
 Glioblastoma multiforme (GBM)
 BCNU wafer implantation for, 28
 survival time in, 9, 9, 20
 Glioblastomas
 MSH6 inactivation and emergent temozolomide resistance in,
 165–169, 166–169
 case example of, 165–166, 166
 clinical study results of, 167–169
 evidence of hypermutator phenotype, 166, 166–167
 prediction of, 167
 standard of care for, 165, 166
 Gliomas
 malignant
 chemotherapy for, 20
 fluorescence-guided resection using ALA, 20–26, 21 (*See also* 5-Aminolevulinic acid)
 gamma knife radiosurgery for, 37t, 39–40
 surgically mediated drug delivery techniques for, 27–33
 radiation therapy for, 20, 27, 38
 role of neurosurgeon in management of, 37–40
 Global neurosurgery, 4, 4
 Glorioso, Joseph, 40

H

Hall, Charles Francis, 6, 7
 Hayes, Isaac, 5, 6
 Health courts, 124
 Hearing loss due to acoustic neuroma, 47, 49, 50
 after radiosurgery, 53–54, 53–54
 after surgery, 3, 35, 48
 Hemorrhage
 after radiosurgery for cavernous malformations, 97–99
 risk from AVMs, 108, 111
 after radiosurgery, 111–112, 112t
 after stereotactic procedures, 79–80, 80t
 Herniated lumbar disc, SPORT study of, 72–74, 73, 74t
 Herpes simplex virus-mediated boost radiosurgery, 40, 40
 History of neurosurgery, 4, 4
 Hypercortisolemia. *See* Cushing's disease
 Hypothalamotomy, radiosurgical ventrolateral, in obesity, 42–43,
 42–43

I

Inflammatory response in spinal cord injury, attenuation by CB₂
 agonist therapy (mouse), 172, 174–175, 175
 Interbody spacers, to enhance spinal fusion, 65, 65
 Interleukin-4 bound to *Pseudomonas* toxin (cpIL4-PE),
 convection-enhanced delivery of, 31
 Interleukin-13 bound to *Pseudomonas* toxin (IL13-PE),
 convection-enhanced delivery of, 30, 30–31
 Intraoperative imaging, 76–85
 for abscess management, 81
 for brain cyst aspiration, 80, 80, 80t
 for brain tumor resection, 12–18

apparent diffusion coefficient maps, 15, 15
 BrainSuite, 160, 161
 diffusion tensor imaging, 17, 17, 20, 160–163, 161–162
 fluorescence-guided resection of gliomas using ALA, 20–
 26, 21
 functional magnetic resonance imaging, 16
 intraoperative stimulation mapping, 17, 18
 magnetic resonance perfusion and cerebral blood volume,
 16, 16–17
 magnetoencephalography, 17
 physiological imaging: magnetic resonance spectroscopy,
 12–15, 15
 quantitative T2 imaging, 15–16, 16
 for cavernous malformations of brainstem, 93
 for craniotomy, 76, 80–81
 development of dedicated stereotactic operating room, 76, 77,
 84, 84–85
 for endoscopic-assisted surgery, 82, 82, 83
 for functional neurosurgery, 76, 81–82, 81t
 history of, 76, 77
 magnetoencephalography, 17
 MRI for tumor surgery, 15–17, 15–17, 160–163
 for stereotactic surgery, 76
 frame-based, 77–79, 77–80, 77t
 frameless, 82–83
 with SurgiScope, 83, 83–84
 Intraoperative stimulation mapping, for tumor resection, 17, 18

J

Jannetta, Peter, 35
 Joint-and-several liability, 122
 Juvenile pilocytic astrocytoma (JPA), 38, 38

K

Kane, Elisha Kent, 8, 8
 Kjellberg, Raymond, 108

L

Laminoplasty, for cervical ossification of posterior longitudinal
 ligament, 129, 129–130
 Language of professional publications, 8–9, 10
 Leksell, Lars, 35, 49, 76, 77, 85, 108
 Light exposure, after ALA administration, 21–22
 LINAC radiosurgery for acoustic neuroma, 50–51
 clinical results of, 55
 stereotactic radiation therapy, 55–56
 Lobotomy, 138–139
 Locomotive function in spinal cord injury, improved by CB₂
 agonist therapy (mouse), 173–174, 174
 Lumbar disc herniation, SPORT study of, 72–74, 73, 74t

M

Magnetic resonance imaging (MRI)
 of cavernous malformations, 97, 98
 of brainstem, 89, 91–92, 91–93

of cervical ossification of posterior longitudinal ligament, 126
of convection-enhanced drug delivery, 31
for craniotomy, 81
for cyst aspiration, 80
development of dedicated stereotactic operating room, 84–85
for frame-based stereotactic surgery, 77, 77–78
for frameless stereotactic surgery, 83
for functional neurosurgery, 81–82
of glioblastoma, 166
of juvenile pilocytic astrocytoma, 38
of petroclival meningioma, 36
for placement of cortical stimulation electrode, 3
for radiosurgery of acoustic neuroma, 50
 follow-up evaluations, 52
 tumor growth control, 53, 54
for radiosurgery of arteriovenous malformations, 110
 postradiosurgery imaging changes, 112, 113, 115
for tumor resection, 20, 160–163
 apparent diffusion coefficient maps, 15, 15
 BrainSuite, 160, 161
 diffusion tensor imaging, 17, 17, 20, 160–163, 161–162
 functional MRI, 16
 magnetic resonance perfusion and cerebral blood volume, 16, 16–17
 quantitative T2 imaging, 15–16, 16
of ventrolateral hypothalamotomy in obese monkey, 42
Magnetic resonance spectroscopy (MRS), for tumor resection, 12–15, 15
Magnetoencephalography (MEG), for tumor resection, 17
Maine Lumbar Spine Study (MLSS), 72
Medical malpractice. *See* Tort system
Melanoma, radiosurgery for brain metastases from, 150–158
Meningioma, petroclival, 36, 36
Monoclonal antibodies, radiolabeled chimeric, convection-enhanced delivery of, 32
MSH6 inactivation and emergent temozolomide resistance in glioblastomas, 165–169, 166–169
 case example of, 165–166, 166
 clinical study results of, 167–169
 evidence of hypermutator phenotype, 166, 166–167
 prediction of, 167
Myelopathy, due to cervical ossification of posterior longitudinal ligament, 126

N

Nansen, 10
Neural network activity mapping, 18, 18
Neurofibromatosis 3, 47, 55, 57
Neurosurgeons
 as explorers, 2–8, 2–12, 10–12
 geographical workforce analysis, 145–148
 role in brain cancer management, 35–44
 gliomas, 37–40, 38, 39, 39t
 herpes simplex virus-mediated boost radiosurgery, 40, 40
 metastatic cancer, 40–42, 41
 Perfexion gamma knife, 43–44, 43–44
 skull base tumors, 35–37, 36, 36t–38t

 role in obesity management, 42–43, 42–43
NeuroWiki, 10, 10
Noneconomic damage caps, 122
Norén, Georg, 35, 49
Nurel-C3, 40, 40

O

Obesity, radiosurgical ventrolateral hypothalamotomy in, 42–43, 42–43
Oligodendroglioma, 38, 39
Oncopolitics, 35–44
Ossification of posterior longitudinal ligament (OPLL), cervical, 126–131
 anterior approach to, 127–129, 128–129, 130
 conservative treatment of, 126–127
 diagnosis of, 126, 127
 discussion of surgical management of, 130
 implants, 130
 intraoperative complications, 130, 131t
 problems in adjacent segments, 130
 etiology of, 126
 laminoplasty for, 129, 129–130
 neurological deficits due to, 126
 surgical indication for, 127
 types of, 126, 127

P

Paclitaxel, convection-enhanced delivery of, 30
Parkinson's disease, stem cell transplants in, 133, 134, 135
Patient indemnity insurance, 124
Peary, Robert, 4, 5, 11, 11, 12
Perfexion gamma knife, 43–44, 43–44
Perry, John, 76
Physical/mechanical strategies to enhance spinal fusion, 67–68, 68, 69
Polar exploration, neurosurgery and, 2–8, 2–12, 10–12
Polyanhydride polymers impregnated with drugs, for malignant gliomas, 27–29, 28, 29
Presidential Address, 1–12
Professional liability insurance (PLI)
 cost of, 145
 physician supply and, 145, 146, 147–148
 tort reform and, 122–123
Proton beam radiosurgery for acoustic neuroma, 50
 clinical results of, 55
Psychosurgery, 138–139
Pulsed electromagnetic fields, to enhance spinal fusion, 67
Punitive damage caps, 122

R

Radiation oncologists, 36–37
Radiation therapy
 for Cushing's disease, 141
 for gliomas, 20, 27, 38
 grade II astrocytoma, 39

for skull base tumors, 37, 37t
 stereotactic, for acoustic neuroma, 55–56
 whole-brain, for brain metastases from melanoma and renal cell carcinoma, 150, 156, 156, 157–158

Radiolabeled chimeric monoclonal antibodies, convection-enhanced delivery of, 32

Radiosurgery
 for arteriovenous malformations, 108–117
 dosage for, 110, 110
 dural AVMs, 116
 early adverse effects of, 112
 embolization before, 116–117
 future directions for, 117
 imaging changes after, 112–113, 113
 initial experience with, 108–109
 late complications of, 114
 management of large AVMs, 115
 management of residual AVM after, 114–115, 115
 permanent sequelae of, 113, 114t
 Pittsburgh experience with, 109–111, 109t
 probability of AVM obliteration with, 112
 risk of hemorrhage after, 111–112, 112t
 staged volume radiosurgery, 115–116
 technical considerations for, 109–111, 110t
 for brain metastases, 37t, 40–42, 41, 44
 for brain metastases from melanoma and renal cell carcinoma, 150–158
 clinical management strategy for, 150–151
 data collection for analysis of, 150
 local control rate for, 154–156, 154t, 155–156, 157
 patient population for, 151, 152t
 planning and implementation of, 151
 response and survival after, 151–154, 152–153, 153t, 157
 statistical analysis of, 151
 whole-brain radiotherapy and, 156, 156, 157–158
 for cavernous malformations, 97–99, 98
 of brainstem, 90, 90t
 hemorrhage protection and, 98–99
 rationale for, 97–98
 results of, 98
 seizure protection and, 99, 104, 106
 for Cushing's disease, 141, 142–143, 143
 for gliomas, 38
 ganglioglioma, 39
 grade II astrocytoma/oligodendroglioma, 39
 juvenile pilocytic astrocytoma, 38, 38
 malignant gliomas, 37t, 39–40
 herpes simplex virus-mediated boost, 40, 40
 history and development of, 35, 76
 indications for, 36t–38t, 85t
 with Perfexion gamma knife, 43–44, 43–44
 for skull base tumors, 36–37
 acoustic neuroma, 35–36, 49, 50–55, 51–54
 petroclival meningioma, 36, 36
 ventrolateral hypothalamotomy in obesity, 42–43, 42–43

Renal cell carcinoma, radiosurgery for brain metastases from, 150–158

Richardson, John, 7–8
 Rosenbaum, Arthur, 76
 Ross, John, 6, 7

S

Sciatica Frequency Index, 72
 Scoresby, William, 8, 8
 Seizures secondary to cavernous malformations, 101–107
 arguments for early surgery in, 102
 case examples of, 104–105, 104–105
 lesionectomy for, 102, 103t, 104
 limitations of, 105–106
 lesionectomy plus electrocorticography-guided resection for, 102–103
 mechanisms of, 106–107
 medical intractability of, 101–102
 postsurgical anti-epileptic drug treatment for, 106
 questions about management of, 101, 106
 radiosurgery for, 99, 104, 106
 safety of surgery for, 106
 subdural electrode monitoring to define epileptogenic zone in, 103–104, 106
 treatment in patients with multiple cavernous malformations, 106
 treatment options for, 102–104
 treatment recommendations for, 105, 105

Shackleton, Ernest, 5

Skull base tumor management, 35–37, 36, 36t–38t
 acoustic neuroma, 35–36
 gamma knife radiosurgery, 36–37, 36t–38t
 new neurological deficits after microsurgery, 36
 petroclival meningioma, 36, 36
 radiation therapy, 37, 37t

Spinal cord injury (SCI), cannabinoid CB₂ receptor activation in (mouse), 172–176
 bladder function improved by, 173, 174, 175, 176
 CB₂ agonist (O-1966) properties and injection, 173
 locomotive function improved by, 173–174, 174
 TNF- α expression decreased by, 172, 174–175, 175

Spinal fusion, enhancement of, 63–69
 bioactive strategies, 65–66, 65t
 bone marrow aspirate and blood spin-down technologies, 64, 66
 bone morphogenetic proteins, 65–66
 composite technologies, 66
 cytokines and other inductive agents, 66
 gene therapy, 66
 biosensing strategies, 68–69, 70
 complexity of bone loading, 68–69, 71
 optimizing bone loading and bone-loading rates, 69
 bone graft substitutes, 63–65
 allograft, 63–64
 components of bone healing, 64
 demineralized bone matrix, 65
 xenograft, 65
 interbody spacers, 65, 65
 phases of bone healing process, 63, 64

physical/mechanical strategies, 67–68, 68, 69
 physiology enhancement and augmentation strategies, 66–67
 direct current stimulation, 67
 electrophysiological strategies, 66–67, 67
 pulsed electromagnetic fields, 67
 surgical technique, 63, 64
 synthetic bone substitutes, 65, 66
 today's and tomorrow's alternatives to autograft, 66
 Spine Patient Outcomes Research Trial (SPORT), 72–75
 of degenerative spondylolisthesis, 75
 of herniated lumbar disc, 72–74, 73, 74t
 Statute of limitations, 122
 Stefansson, Vilhjalmur, 9, 9
 Steiner, Ladislau, 108
 Stem cells, 133–136
 adult, 135–136
 bone marrow or mesenchymal, 136
 generation of, 133
 neural, 133–135
 development from embryonic stem cells, 133, 134
 endogenous, 133
 NT2 cell line, 133–134
 role of neurotrophic and angiogenic factors in
 transplantation of, 134–135
 transplantation in Parkinson's disease, 133, 134, 135
 umbilical cord blood cells in stroke, 136
 Stereotactic procedures, 76–85
 for brain abscess, 81
 for brain cyst, 80, 80, 80t
 craniotomy, 76, 80–81
 development of dedicated stereotactic operating room, 76, 77,
 84, 84–85
 for endoscopic-assisted surgery, 82, 82, 83
 frame-based, 77–79, 77–80, 77t
 for biopsy, 78, 79
 brain hemorrhage after, 79–80, 80t
 complications of, 79–80, 79t–80t
 frameless, 82–83
 functional neurosurgery, 76, 81–82, 81t
 radiosurgery (*See* Radiosurgery)
 Stereotactic radiation therapy (SRT), for acoustic neuroma, 55–56
 Stroke, umbilical cord blood cells in, 136
 Surgical Planning System SPS, 84
 SurgiScope, 83, 83–84
 Synthetic bone substitutes, to enhance spinal fusion, 65, 66

T

Temozolomide resistance in glioblastomas, *MSH6* inactivation

and, 165–169, 166–169
 case example of, 165–166, 166
 clinical study results of, 167–169
 evidence of hypermutator phenotype, 166, 166–167
 prediction of, 167
 Tf-CRM111, convection-enhanced delivery of, 30–31
 Tinnitus, after acoustic neuroma removal, 48
 Tort system, 121–125
 alternatives to, 123–124
 for birth-related injuries in Florida and Virginia, 124
 “early offer” plan, 124
 health courts, 124
 in New Zealand, 123
 patient indemnity insurance, 124
 in Scandinavian countries, 123–124
 description of, 121
 “mainstream” tort reform measures, 122
 Alternative Dispute Resolution, 122
 collateral-source payments, 122
 contingency fee, 122
 effects of, 122–123
 expert witness requirements, 122
 healthcare costs and, 123
 joint-and-several liability, 122
 malpractice insurance premiums and, 122–123
 noneconomic damage caps, 122
 punitive damage caps, 122
 statute of limitations, 122
 problems with U.S. system, 121–122
 TP-38, convection-enhanced delivery of, 30
 Trigeminal nerve function, after acoustic neuroma radiosurgery,
 55
 Tumor necrosis factor- α (TNF- α) in spinal cord injury, decreased
 by CB₂ agonist therapy (mouse), 172, 174–175, 175

U

Umbilical cord blood cells, in stroke, 136

V

Ventrolateral radiosurgical hypothalamotomy, in obesity, 42–43,
 42–43
 Vestibular schwannoma. *See* Acoustic neuroma

X

Xenograft, to enhance spinal fusion, 65